BioSpace News Archive

Cardinal Health plans to release fourth-quarter and year-end financial results for its fiscal year 2021 on August 5 prior to the opening of trading on the New York Stock Exchange.

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug and Administration has maintained Priority Review for the Company’s Abbreviated New Drug Application for vasopressin.

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives, announced the pricing of its initial public offering of 4,800,000 shares of common stock at a price to the public of $9.00 per share.

Aileron Therapeutics, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced that it will be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021.

Verastem Oncology, a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced the appointments of Paul Bunn, M.D., and Lesley Solomon to its Board of Directors, adding additional strength in the areas of academic research and business innovation.

Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute at the University of Utah and began treating patients on May 11th with the MEVION S250i Proton Therapy System®.

EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, announced a strategic research and development collaboration agreement.